Summary
Vitamin D analogues of high biological activity are probably useful in the treatment of renal osteodystrophy. The pharmacokinetics of the synthetic compound 5,6-trans-25-hydroxycholecalciferol have been studied in healthy subjects who were of normal vitamin D status. In comparison to natural 25-hydroxy-cholecalciferol, serum levels of the analogue were lower and its half-life in blood after oral or intravenous administration was considerably shorter. In normal subjects no increase of dihydroxylated metabolites in serum was observed within seven days of an intravenous dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ritz, E., Krempien, B., Bommer, J., Malluche, H., Mehls, O.: Skelettveränderungen bei beginnender Einschränkung der Nierenfunktion. Nierenund Hochdruckkrankheiten3, XI (1974)
Stanbury, S.W.: Osteomalacia. Clin. Endocr. Metab.1 239–266 (1972)
Kleeman, C.R., Better, O.S.: Disordered divalent ion metabolism in kidney disease: comments on pathogenesis and treatment. Kidney Int.4 73–79 (1973)
Coburn, J.W., Norman, A.W.: Role of the kidney in the metabolism of calciferol (vitamin D). Clin. Nephrol.1 273–283 (1973).
Norman, A.W., Midgett, R.J., Myrtle, J.F., Nowicki, H.G.: Studies on calciferol metabolism. I. Production of vitamin D metabolite 4B from 25-OH-cholecalciferol by kidney homogenates. Biochem. biophys. Res. Commun.42 1082–1087 (1971)
Schaefer, K., von Herrath, D., Stratz, R.: Metabolism of 1,2 H3-4-C14-cholecalciferol in normal, uremic, and anephric subjects. Israel J. med. Sci.8 80–83 (1972)
Mawer, E.B., Backhouse, J., Taylor, C.M., Lumb, G.A., Stanbury, S.W.: Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet1973 I 626–628
Avioli, L.V., Haddad, J.G.: Vitamin D: current concepts. Metabolism22 507–531 (1973)
Brickman, A.S., Coburn, J.W., Norman, A.W.: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. New Engl. J. Med.287 891–895 (1972)
Henderson, R.G., Russel, R.G.G., Ledingham, J.G.G., Smith, R., Oliver, D.O., Walton, R.J., Small, D.G., Preston, C., Warner, G.T., Norman, A.W.: Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet1974 I 379–384
Lumb, G.A., Mawer, E.B., Stanbury, S.W.: The apparent vitamin D resistance of chronic renal failure. Amer. J. Med.50 421–441 (1971)
Peacock, M., Gallagher, J.C., Nordin, B.E.C.: Action of 1 α-hydroxy vitamin D3 on calcium absorption and bone resorption in man. Lancet1974 I 385–389
Kaneko, C., Yamada, S., Sugimoto, A., Suda, T., Suzuku, M., Kakuta, S., Sasaki, S.: Synthesis and biological activity of 1 α-hydroxyvitamin D3. Steroids23 75–92 (1974)
Kaye, M., Sagar, S.: Dihydrotachysterol in uremia. Clin. Res.19 809 (1971)
Kaye, M., Sagar, S.: Effect of dihydrotachysterol on calcium absorption in uremia. Metabolism21 815–824 (1972)
Holick, M.F., Garabedian, M., Deluca, H.F.: 5, 6-trans-isomers of cholecalciferol and 25-hydroxycholecalciferol. Substitutes for 1,25-dihydroxycholecalciferol in anephric animals. Biochemistry11 2715–2719 (1972)
von Herrath, D., Schaefer, K., Kraft, D., Grigoleit, H.-G., Koeppe, P.: Treatment of uremic bone disease: action of 5, 6-trans-25-hydroxycholecalciferol (a vitamin D-analog) in chronic renal failure. Klin. Wschr.51 979–981 (1973)
von Herrath, D., Kraft, D., Grigoleit, H.-G., Schaefer, K.: Die Behandlung der urämischen Osteopathie. II. Die Wirkung von 5, 6-trans-25-Hydroxycholecalciferol bei terminaler Niereninsuffizienz. Dtsch. med. Wschr.98 1379–1381 (1973)
Schaefer, K., Kraft, D., von Herrath, D., Grigoleit, H.-G.: Tissue distribution of radioactive 5, 6-trans-25-hydroxycholecalciferol in vitamin D-deficient rats. IRCS Med. Sciences2 1112 (1974)
Offermann, G., von Herrath, D., Schaefer, K.: Serum 25-hydroxycholecalciferol in uremia. Nephron13 269–277 (1974)
Schaefer, K., von Herrath, D., Opitz, A., Koch, H.-U., Stratz, R.: The metabolic fate of (26.27)3H-25-hydroxyvitamin D3 in normal uremic and rachitic rats. Europ. J. clin. Invest.2 133–140 (1972)
Ponchon, G., DeLuca, H.F.: Metabolites of vitamin D3 and their biologic activity. J. Nutr.99 157–167 (1969)
Mawer, E.B., Backhouse, J.: An improved system for the separation of metabolites of isotopically labelled vitamin D3 on silicic acid columns. Biochem. J.112 255–256 (1969)
Koeppe, P., Höffler, D.: Die Verwendung eines Digitalrechners zur Entwicklung von Dosierungsempfehlungen für die Antibiotikatherapie. Drug Res.21 311–319 (1972)
Offermann, G.: Methoden und Ergebnisse der 25-OH-Vitamin-D3-Bestimmung im kompetitiven Proteinbindungsassay. Münch. med. Wschr.116 1569–1572 (1974)
Schaefer, K., Opitz, A., Stratz, R., Koch, H.-U., von Herrath, D.: Der Stoffwechsel von 25-Hydroxycholecalciferol bei gesunden und nephrektomierten Patienten. Dtsch. med. Wschr.96 798–799 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Offermann, G., Schaefer, K., Grigoleit, H.G. et al. Pharmacokinetics of 5,6-trans-25-hydroxycholecalciferol, a synthetic analogue of vitamin D3, in man. Eur J Clin Pharmacol 8, 255–260 (1975). https://doi.org/10.1007/BF00567124
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00567124